These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Latta EK; Tjan S; Parkes RK; O'Malley FP Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013 [TBL] [Abstract][Full Text] [Related]
4. Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Carter MR; Hornick JL; Lester S; Fletcher CD Am J Surg Pathol; 2006 Mar; 30(3):300-9. PubMed ID: 16538049 [TBL] [Abstract][Full Text] [Related]
5. Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Dakin Haché K; Gray S; Barnes PJ; Dewar R; Younis T; Rayson D Breast Cancer Res Treat; 2007 Oct; 105(2):169-75. PubMed ID: 17268818 [TBL] [Abstract][Full Text] [Related]
6. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528 [TBL] [Abstract][Full Text] [Related]
8. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090 [TBL] [Abstract][Full Text] [Related]
9. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Hussein MR; Abd-Elwahed SR; Abdulwahed AR Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077 [TBL] [Abstract][Full Text] [Related]
10. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
11. Metaplastic breast carcinomas and their relationship with basal-like phenotype. Cakir A; Gönül II; Uluoğlu O Turk Patoloji Derg; 2012; 28(2):134-41. PubMed ID: 22627631 [TBL] [Abstract][Full Text] [Related]
12. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan. Sharif MA; Mamoon N; Mushtaq S; Khadim MT J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313 [TBL] [Abstract][Full Text] [Related]
13. Metaplastic breast carcinoma: a cytohistologic and clinical study of 10 cases. Johnson TL; Kini SR Diagn Cytopathol; 1996 May; 14(3):226-32. PubMed ID: 8732652 [TBL] [Abstract][Full Text] [Related]
14. Breast carcinoma in women 35 years and younger: a pathological study. Fernandopulle SM; Cher-Siangang P; Tan PH Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742 [TBL] [Abstract][Full Text] [Related]
15. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575 [TBL] [Abstract][Full Text] [Related]
16. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization. Wang X; MacLennan GT; Zhang S; Montironi R; Lopez-Beltran A; Tan PH; Foster S; Baldridge LA; Cheng L Hum Pathol; 2009 Feb; 40(2):211-7. PubMed ID: 18799188 [TBL] [Abstract][Full Text] [Related]
17. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset? Fadare O; Wang SA; Hileeto D Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623 [TBL] [Abstract][Full Text] [Related]
18. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Steinman S; Wang J; Bourne P; Yang Q; Tang P Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367 [TBL] [Abstract][Full Text] [Related]
19. Study of HER2/neu status in Qatari women with breast carcinoma. Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666 [TBL] [Abstract][Full Text] [Related]
20. Metaplastic breast carcinoma: clinicopathologic features and prognostic value of triple negativity. Lim KH; Oh DY; Chie EK; Han W; Im SA; Kim TY; Park IA; Noh DY; Ha SW; Bang YJ Jpn J Clin Oncol; 2010 Feb; 40(2):112-8. PubMed ID: 19887523 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]